An Open-label Extension Study to Investigate Safety and Tolerability of ML-004 in Adolescents and Adults with Autism Spectrum Disorders (ASD).
Latest Information Update: 26 Mar 2025
At a glance
- Drugs ML-004 (Primary)
- Indications Pervasive child development disorders
- Focus Adverse reactions
- Sponsors MapLight Therapeutics
Most Recent Events
- 14 Mar 2025 Planned End Date changed from 1 Jun 2026 to 1 Dec 2027.
- 14 Mar 2025 Planned primary completion date changed from 1 May 2026 to 1 Nov 2027.
- 24 Jul 2023 Planned End Date changed from 1 Sep 2025 to 1 Jun 2026.